In adult and pediatric patients 12 years and older
Intervene with Jakafi® (ruxolitinib) at the first sign of steroid-refractory aGVHD1

Because of the risk of progression of acute GVHD, early identification and timely action are critical.
Michael R. Bishop, MD, GVHD Expert
INDICATION
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
REACH1 primary endpoint
- ORR at day 28: 57% (28/49) of patients treated with Jakafi achieved a response (95% CI, 42-71)1
REACH2 primary endpoint
- ORR at day 28: 62% (96/154) of patients treated with Jakafi achieved a response vs 39% (61/155) in the control arm (OR, 2.64; 95% CI, 1.65-4.22; P<0.001)2
Identify when to treat
The EBMT-NIH-CIBMTR task force provides guidance in aGVHD
Explore response rates across organs
Learn about REACH1 results and a subgroup analysis by organ
Safety profile
Review the safety profile from the REACH1 and REACH2 trials
See cytopenia data
Review platelet and neutrophil counts over time in the REACH2 trial

Connect patients to benefits with IncyteCARES
Call 1-855-452-5234 (Monday through Friday, 8 AM to 8 PM ET) or visit hcp.IncyteCARES.com.
*Category 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.3
†The National Comprehensive Cancer Network® (NCCN®) does not recommend one systemic agent as preferred over another in SR GVHD.3 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation V.2.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed December 16, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
aGVHD=acute graft-versus-host disease; BAT=best available therapy; CI=confidence interval; CIBMTR=Center for International Blood and Marrow Transplant Research; EBMT=European Society for Blood and Marrow Transplantation; HCT=hematopoietic cell transplantation; NCCN=National Comprehensive Cancer Network® (NCCN®); NIH=National Institutes of Health; OR=odds ratio; ORR=overall response rate; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid refractory.
References: 1. Jakafi Prescribing Information. Wilmington, DE: Incyte Corporation. 2. Zeiser R, von Bubnoff N, Butler J, et al; for the REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host-disease. N Engl J Med. 2020;382(19):1800-1810. Supplementary appendix available at: https://www.nejm.org/doi/10.1056/NEJMoa1917635. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation V.2.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed December 16, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.